

Supplementary Data

SUPPLEMENTARY TABLE S1. NIGHT-TIME SENSOR GLUCOSE, GLYCEMIC CONTROL, VARIABILITY, AND INSULIN DELIVERED DURING THE RUN-IN AND STUDY PHASE

	<i>Run-in phase</i>	<i>Study phase</i>	P
SG, mg/dL	166±26 (163, 148–184)	155±13 (153, 145–162)	<0.001
Percentage of sensor glucose values across ranges, mg/dL			
≤50	1.0±1.6 (0.3, 0.0–1.2)	0.5±0.6 (0.3, 0.1–0.7)	0.0125 [†]
≤54	1.5±2.2 (0.5, 0.0–2.0)	0.7±0.7 (0.5, 0.2–1.0)	<0.001 [†]
≤60	2.4±3.2 (1.2, 0.4–3.5)	1.2±1.0 (0.8, 0.4–1.6)	<0.001 [†]
≤70	4.9±5.2 (3.3, 1.4–7.4)	2.4±1.6 (1.9, 1.1–3.5)	<0.001 [†]
70–140	35.4±14.7 (35.0, 24.6–46.2)	48.6±8.1 (48.9, 42.4–54.1)	<0.001
>70–180	56.6±15.3 (57.5, 47.7–67.4)	70.9±9.4 (72.0, 64.3–77.6)	<0.001 [†]
>180	38.5±16.7 (37.6, 27.8–49.0)	26.7±9.0 (25.7, 20.1–33.1)	<0.001
>250	11.7±8.9 (9.7, 4.7–17.4)	7.8±5.1 (6.8, 3.6–11.0)	<0.001 [†]
>300	3.8±4.0 (2.6, 0.4–5.7)	2.6±2.4 (1.9, 0.8–3.5)	<0.001 [†]
Within-day SD of SG, mg/dL	42.1±7.9 (43.2, 37.0–47.4)	39.6±6.3 (39.1, 34.8–44.2)	<0.001 [†]
Within-day CV of SG, %	26.2±4.7 (25.6, 23.2–29.5)	25.5±3.0 (25.6, 23.6–27.4)	0.1079
TDD, U/(kg·d)*	0.2±0.1 (0.2, 0.2–0.2)	0.2±0.0 (0.2, 0.2–0.2)	0.0572
Basal insulin as % of TDD*	72.2±11.7 (73.8, 63.9–82.7)	75.9±7.9 (76.5, 72.5–82.0)	<0.001

The run-in phase duration was 2 weeks and the study phase duration was 3 months. All values are shown as mean±SD (median, interquartile range).

*One participant's height and weight were not captured at enrollment.

[†]Wilcoxon signed-rank test.

CV, coefficient of variation; SD, standard deviation; SG, sensor glucose; TDD, total daily dose of insulin, includes basal + microbolus.